200 related articles for article (PubMed ID: 36575360)
1. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.
Portuguese AJ; Gauthier J; Tykodi SS; Hall ET; Hirayama AV; Yeung CCS; Blosser CD
Bone Marrow Transplant; 2023 Apr; 58(4):353-359. PubMed ID: 36575360
[TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.
McKenna M; Epperla N; Ghobadi A; Liu J; Lazaryan A; Ibrahim U; Jacobson CA; Naik SG; Nastoupil L; Chowdhury SM; Voorhees TJ; Jacobs MT; Farooq U; Osman K; Olszewski AJ; Ahmed S; Evens AM
Br J Haematol; 2023 Jul; 202(2):248-255. PubMed ID: 37129856
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
Kline K; Chen W; Kallen ME; Koka R; Omili D; Fan X; Iraguha T; Gebru E; Dishanthan N; Baker JM; Dietze KA; Yared JA; Hankey K; Dahiya S; Niederhaus SV; Dunleavy K; Hardy NM; Luetkens T; Rapoport AP; Atanackovic D
Hum Vaccin Immunother; 2023 Aug; 19(2):2216116. PubMed ID: 37278257
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
6. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.
Hernani R; Sancho A; Amat P; Hernández-Boluda JC; Pérez A; Piñana JL; Carretero C; Goterris R; Gómez M; Saus A; Ferrer B; Teruel AI; Terol MJ; Solano C
Curr Res Transl Med; 2021 Oct; 69(4):103304. PubMed ID: 34303899
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Feng M; Luo C; Wan X; Pan C; Tang J; Xue F; Yin M; Lu D; Xia Q; Li B; Chen J
Cell Transplant; 2021; 30():963689721996649. PubMed ID: 33631963
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.
Luttwak E; Hagin D; Perry C; Wolach O; Itchaki G; Amit O; Bar-On Y; Freund T; Kay S; Eshel R; Avivi I; Ram R
Bone Marrow Transplant; 2021 May; 56(5):1031-1037. PubMed ID: 33230187
[TBL] [Abstract][Full Text] [Related]
9. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.
Krishnamoorthy S; Ghobadi A; Santos RD; Schilling JD; Malone AF; Murad H; Bartlett NL; Alhamad T
Am J Transplant; 2021 Feb; 21(2):809-814. PubMed ID: 33089906
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
11. Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.
de Nattes T; Camus V; François A; Dallet G; Ferrand C; Guerrot D; Lemoine M; Morin F; Thieblemont C; Veresezan EL; Candon S; Latouche JB; Bertrand D
Am J Kidney Dis; 2022 May; 79(5):760-764. PubMed ID: 34461166
[TBL] [Abstract][Full Text] [Related]
12. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
13. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
15. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
[TBL] [Abstract][Full Text] [Related]
17. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
[TBL] [Abstract][Full Text] [Related]
18. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.
Ibrahim U; Bassil C; Chavez JC; Khimani F; Jain MD; Locke FL; Osman K; Lazaryan A
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):772-778. PubMed ID: 37263876
[No Abstract] [Full Text] [Related]
19. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
